Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 5Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Radiation Pneumonitis 2Peritoneal Neoplasms 2Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophagogastric Adenocarcinoma 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Octreotide 5Everolimus 4pasireotide 3lanreotide 3ganitumab 2gallium Ga 68 dotatate 2cabozantinib 2Nivolumab 2Erlotinib Hydrochloride 2surufatinib 1pertuzumab 1nintedanib 1ibrutinib 1fosbretabulin 1conatumumab 1cixutumumab 1carfilzomib 1arginyllysine 1aflibercept 1Temozolomide 1Sunitinib 1Somatostatin 1Random Allocation 1Ramucirumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Capecitabine 1Bevacizumab 1Axitinib 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × nintedanib × Clear all
NCT02399215 2023-12-26

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 2 Completed
32 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡